| MeSH term | MeSH ID | Detail |
|---|---|---|
| Tenosynovitis | D013717 | 3 associated lipids |
| Splenic Diseases | D013158 | 5 associated lipids |
| Hernia, Hiatal | D006551 | 3 associated lipids |
| Chlamydial Pneumonia | D061387 | 2 associated lipids |
| Leprosy, Lepromatous | D015440 | 2 associated lipids |
| Gastritis, Hypertrophic | D005758 | 1 associated lipids |
| Hypoproteinemia | D007019 | 1 associated lipids |
| Cutaneous Fistula | D017577 | 1 associated lipids |
| Tuberculosis, Ocular | D014392 | 1 associated lipids |
| Euthyroid Sick Syndromes | D005067 | 1 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Guelar A et al. | [Therapeutic alternatives for cases of cerebral toxoplasmosis in patients with AIDS: clarithromycin and atovaquone]. | 1994 | Enferm. Infecc. Microbiol. Clin. | pmid:8011719 |
| Aspin MM et al. | Comparative study of the safety and efficacy of clarithromycin and amoxicillin-clavulanate in the treatment of acute otitis media in children. | 1994 | J. Pediatr. | pmid:8021763 |
| Chaisson RE et al. | Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. | 1994 | Ann. Intern. Med. | pmid:7978715 |
| Goldberger M and Masur H | Clarithromycin therapy for Mycobacterium avium complex disease in patients with AIDS: potential and problems. | 1994 | Ann. Intern. Med. | pmid:7978725 |
| Saran BR et al. | Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin. | 1994 | Arch. Ophthalmol. | pmid:8085960 |
| Yew WW et al. | Cholestatic hepatitis in a patient who received clarithromycin therapy for a Mycobacterium chelonae lung infection. | 1994 | Clin. Infect. Dis. | pmid:8086541 |
| Zahid MA et al. | Mycobacterium chelonae (M. chelonae subspecies chelonae): report of a patient with a sporotrichoid presentation who was successfully treated with clarithromycin and ciprofloxacin. | 1994 | Clin. Infect. Dis. | pmid:8086568 |
| Labenz J | [Helicobacter pylori therapy with omeprazole and clarithromycin: current status]. | 1994 | Leber Magen Darm | pmid:7968179 |
| Oteo JA et al. | Clarithromycin-induced thrombocytopenic purpura. | 1994 | Clin. Infect. Dis. | pmid:7888564 |
| Bermudez LE et al. | Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice. | 1994 | Antimicrob. Agents Chemother. | pmid:7695252 |
| Yamada S et al. | [A child with iritis due to Chlamydia pneumoniae infection]. | 1994 | Kansenshogaku Zasshi | pmid:7876679 |
| Tessier MH et al. | Clarithromycin for atypical mycobacterial lymphadenitis in non-immunocompromised children. | 1994 Dec 24-31 | Lancet | pmid:7997032 |
| Mor N et al. | Accumulation of clarithromycin in macrophages infected with Mycobacterium avium. | 1994 Jan-Feb | Pharmacotherapy | pmid:8159593 |
| Winter J | Intravenous clarithromycin. | 1994 Mar 16-Apr 5 | Br J Hosp Med | pmid:8032567 |
| Gersema LM et al. | Suspected drug interaction between cyclosporine and clarithromycin. | 1994 Mar-Apr | J. Heart Lung Transplant. | pmid:8031821 |
| Heifets LB | Quantitative cultures and drug susceptibility testing of Mycobacterium avium clinical isolates before and during the antimicrobial therapy. | 1994 Mar-Apr | Res. Microbiol. | pmid:7809471 |
| Dautzenberg B | Clinical trials in Mycobacterium avium therapy: lessons to take home. | 1994 Mar-Apr | Res. Microbiol. | pmid:7809472 |
| Scaglione F et al. | Effect of antibiotics on Bordetella pertussis adhering activity: hypothesis regarding mechanism of action. | 1994 May-Jun | Chemotherapy | pmid:7515782 |
| O'Connor NK and Fris J | Clarithromycin-carbamazepine interaction in a clinical setting. | 1994 Nov-Dec | J Am Board Fam Pract | pmid:7847111 |
| Cama VA et al. | Treatment of acute and chronic Cryptosporidium parvum infections in mice using clarithromycin and 14-OH clarithromycin. | 1994 Sep-Oct | J. Eukaryot. Microbiol. | pmid:7804227 |
| FDA approves Biaxin for MAC prophylaxis. Food and Drug Administration. | 1995 | J Int Assoc Physicians AIDS Care | pmid:11363096 | |
| Savarino V et al. | Helicobacter pylori eradication and reinfection. | 1995 | Lancet | pmid:7783564 |
| Comley JC and Sterling AM | Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice. | 1995 | Antimicrob. Agents Chemother. | pmid:7785975 |
| Weits J and Sprenger HG | [Surgical treatment of lymphadenitis caused by non-tuberculous mycobacteria in children]. | 1995 | Ned Tijdschr Geneeskd | pmid:8524431 |
| Nash KA and Inderlied CB | Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. | 1995 | Antimicrob. Agents Chemother. | pmid:8592991 |
| Midoneck SR and Etingin OR | Clarithromycin-related toxic effects of digoxin. | 1995 | N. Engl. J. Med. | pmid:7477159 |
| Ishii K et al. | A new pharmacokinetic model including in vivo dissolution and gastrointestinal transit parameters. | 1995 | Biol. Pharm. Bull. | pmid:7550125 |
| Harris AW et al. | Eradication of Helicobacter pylori with lansoprazole and clarithromycin. | 1995 | Aliment. Pharmacol. Ther. | pmid:7605863 |
| Katelaris PH et al. | A randomized prospective comparison of clarithromycin versus amoxycillin in combination with omeprazole for eradication of Helicobacter pylori. | 1995 | Aliment. Pharmacol. Ther. | pmid:7605864 |
| Yousfi MM et al. | Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. | 1995 | Aliment. Pharmacol. Ther. | pmid:7605865 |
| Chevalley GF et al. | [Uveitis associated with rifabutin treatment. Apropos of 3 patients]. | 1995 | Klin Monbl Augenheilkd | pmid:7609395 |
| Blum AL et al. | [Functional dyspepsia: approaches to Helicobacter pylori eradication therapy]. | 1995 | Leber Magen Darm | pmid:7609589 |
| Lacassin F et al. | Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency virus. | 1995 | Antimicrob. Agents Chemother. | pmid:7695324 |
| Labenz J and Börsch G | Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers. | 1995 | Am. J. Gastroenterol. | pmid:7733070 |
| Forné M et al. | Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study. | 1995 | Am. J. Gastroenterol. | pmid:7733075 |
| Moayyedi P et al. | Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. | 1995 | Eur J Gastroenterol Hepatol | pmid:8574714 |
| Fujioka T et al. | Peptic ulcer recurrence after Helicobacter pylori eradication: a 5-year follow-up study. | 1995 | Eur J Gastroenterol Hepatol | pmid:8574733 |
| Deltenre M et al. | Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. | 1995 | Eur J Gastroenterol Hepatol | pmid:8574734 |
| Fukuda Y et al. | Combination therapy with mucosal protective agent for the eradication of Helicobacter pylori. | 1995 | Eur J Gastroenterol Hepatol | pmid:8574735 |
| Graham DY | Clarithromycin for treatment of Helicobacter pylori infections. | 1995 | Eur J Gastroenterol Hepatol | pmid:8574737 |
| Takimoto T et al. | Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori. | 1995 | Eur J Gastroenterol Hepatol | pmid:8574739 |
| Pavlopoulou J et al. | Randomized controlled study of clarithromycin versus cefaclor suspensions in the treatment of acute otitis media in children. | 1995 | J Chemother | pmid:8904139 |
| Lounis N et al. | Selection of clarithromycin-resistant Mycobacterium avium complex during combined therapy using the beige mouse model. | 1995 | Antimicrob. Agents Chemother. | pmid:7793860 |
| Fattorini L et al. | In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium. | 1995 | Antimicrob. Agents Chemother. | pmid:7793873 |
| Cohen Y et al. | Use of normal C57BL/6 mice with established Mycobacterium avium infections as an alternative model for evaluation of antibiotic activity. | 1995 | Antimicrob. Agents Chemother. | pmid:7793882 |
| Furney SK et al. | Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model. | 1995 | Antimicrob. Agents Chemother. | pmid:7793895 |
| Brown BA et al. | Clarithromycin-induced hepatotoxicity. | 1995 | Clin. Infect. Dis. | pmid:7795060 |
| Raffi F et al. | Breakthrough cerebral toxoplasmosis in patients with AIDS who are being treated with clarithromycin. | 1995 | Clin. Infect. Dis. | pmid:7795062 |
| Sharma PK and Tami TA | AIDS: lessons from the last decade and prospects for the future. | 1995 | Ear Nose Throat J | pmid:7796740 |
| Researchers find new drugs to fight MAC. | 1995 | AIDS Alert | pmid:11362925 |